Study of immunological aspects of aspergillosis in mice and effect of polyene macrolide antibiotic (SJA-95) and IFN-γ: A possible role of IFN-γ as an adjunct in antifungal therapy

Immunology Letters

Volumn 141, Issue 1, 2011, Pages 68-73

  Naik, Suresh R ^a   Thakare, Vishnu N ^a   Desai, Sandhya K ^b   Rahalkar, Prabhakar R ^c  

^a Sinhgad Institute of Pharmaceutical Sciences   (India)

^b PRIN K M KUNDNANI COLLEGE OF PHARMACY   (India)

^c Hindustan Antibiotics Ltd   (India)

Author keywords

Aspergillosis; IFN ; Liposomal SJA 95; Serum IgG; Serum IL 4; SJA 95

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 4; LIPOSOME; MACROLIDE; POLYENE ANTIBIOTIC AGENT; SJA 95; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; BIOCHEMISTRY; BRAIN; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; IMMUNE RESPONSE; KIDNEY; LIVER; LUNG; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPLEEN; SURVIVAL TIME;

ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; IMMUNOGLOBULIN G; IMMUNOMODULATION; INTERFERON-GAMMA; INTERLEUKIN-4; LIPOSOMES; LIVER; LUNG; MACROLIDES; MICE; MICE, INBRED BALB C; POLYENES; SPLEEN;

EID: 80955130854     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.07.008     Document Type: Article

References (32)

1. Choi H.S., Choi J.Y., Yoon J.S., Kim S.J., Lee S.Y. Clinical characteristics and prognosis of orbital invasive aspergillosis. Ophthal Plast Reconstr Surg 2008, 24:454-459.
2. Roilides E., Uhlig C., Venzon D., Pizzo P.A., Walsh T.J. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immune 1993, 61:1185-1193.
3. Roilides E., Uhlig C., Venzon D., Pizzo P.A., Walsh T.J. Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immune 1993, 61:4870-4877.
4. Roilides E., Walsh T.J., Pizzo P.A., Rubin M. Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 1991, 163:579-583.
5. Graybill J., Bocanegra R., Luther M. Antifungal combination therapy with granulocyte colony-stimulating factor and fluconazole in experimental disseminated candidiasis. Eur J Clin Microbiol Infect Dis 1995, 14:700-703.
6. Graybill J., Bocanegra R., Najvar L., Loebenberg D., Luther M. Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Antimicrob Agents Chemother 1998, 42:2467-2473.
7. Sionov E., Segal E. Polyene and cytokine treatment of experimental aspergillosis. FEMS Immunol Med Microbiol 2003, 39:221-227.
8. 2-type profile. J Invest Dermatol 1994, 103:29-33.
9. Desai S.K., Naik S.R. Probable mechanism(s) of antifungal activity of SJA-95, a heptaene polyene antibiotic. Ind J Pharm Sci 2008, 70:165-169.
10. Desai S.K., Naik S.R. Chemotherapeutic activity of liposomal SJA-95: a new polyene macrolide antibiotic in experimental aspergillosis and cryptococcosis. Biomed Pharmacother 2009, 63:287-292.
11. Harindran J., Gupte T.E., Naik S.R. HA-1-92, A new antifungal antibiotic produced by Streptomyces CDRIL-312: fermentation, isolation, purification and biological activity. World J Microbiol Biotech 1999, 15:425-430.
12. Chakraborty K.K., Naik S.R. Therapeutic and hemolytic evaluation of in situ liposomal preparation containing amphotericin-beta complexed with different chemically modified beta-cyclodextrins. J Pharm Pharm Sci 2003, 6:231-237.
13. Naik S.R., Desai S.K., Nanda R.K., Narayanan M.S. Fermentation, isolation, purification and biological activity of SJA-95, a heptene polyene macrolide antibiotic produced by strain S-24. Arzneimittel Forschung (Drug Res) 2007, 57:171-179.
14. Harizi H., Juzan M., Pitard V., Moreau J.F., Gualde N. Cyclooxygenase-2-issued prostaglandin E2 enhances the production of endogenous IL-10, which down regulates dendritic cell functions. J Immunol 2002, 168:2255-2263.
15. Surolia A., Bachhawat B.K., Podder S.K. Interaction between lectin from Ricinus communis and liposomes containing ganglisodides. Nature 1975, 257:802-804.
16. Ahmad I., Sarkar A.K., Bachhawat B.K. Liposomal amphotericin B in the control of experimental aspergillosis in mice: part I: relative therapeutic efficacy of free and liposomal amphotericin B. Ind J Biochem Biophys 1989, 26:351-436.
17. Snedecor W.G., Cochran G.W. Statistical Methods 1989, Iowa State University Press, Chapter 5. eighth ed.
18. Samarasinghe A., Hoselton S., Schuh J. A comparison between intratraccheal and inhalation delivery of Aspergillus fumigatus conidia in the development of fungal allergic asthma in G57BL/6 mice. Fungal Biol 2011, 115:21-29.
19. Stevens D.A., Kan V.L., Judson M.A. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000, 30:696-699.
20. Mehrad B., Strieter R.M., Standiford T.J. Role of TNF-alpha in pulmonary host defense in murine invasive aspergillosis. J Immunol 1999, 162:1633-1640.
21. Zhong S., Stevenson M.M. IL-12 is required for antibody-mediated protective immunity against blood-stage Plasmodium chabaudi AS malaria infection in mice. J Immunol 2002, 168:1348-1355.
22. Cenci E., Mencacci A., d'Ostiani C.F., Del Sero G., Mosci P., Montagnoli C., et al. Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis 1998, 178:1750-1760.
23. Cenci E., Mencacci A., Del Sero G., Bacci A., Montagnoli C., d'Ostiani C.F., et al. L. Interleukin-4 causes susceptibility to invasive pulmonary aspergillosis through suppression of protective type I response. J Infect Dis 1999, 180:1957-1968.
24. Romani L., Howard D.H. Mechanisms of resistance to fungal infections. Curr Opin Immunol 1995, 7:517-523.
25. Romani L., Kaufmann S.H. Editorial overview: immunity to fungi. Res Immunol 1998, 149:277-281.
26. Mukherjee S., Lee S.C., Casadevall A. Antibodies to Cryptococcus neofromans glucurnonoxylomannan enhance antifungal activity of murine macrophages. Infect immunol 1995, 63:573-579.
27. Tonetti L., Spaccapello R., Cenci E., Mencacci A., Pucceti R., Coffmann L., et al. Interleukin-4 and IL-10 exacerbate candidiasis in mice. Eur J Immunol 1995, 25:1559-1565.
28. Káposzta R., Tree P., Marodi L., Gordon S. Characteristic of invasive Candidiasis in gamma interferon and interleukin-4 deficient mice. Role of macrophages in host defense against Candida albicans. Infect Immun 1998, 66:1708-1717.
29. Nagai H., Guo H., Choi H., Kurup V. Interferon-γ and tumor necrosis factor-α protect mice from invasive aspergillosis. J Infect Dis 1995, 172:1554.
30. Gobin S.J.P., Peijnenburg A., Keijsers V., Van den Elsen P.J. Site α is crucial for IFN-γ induced MHC class I transactivation. Immunol Lett 1997, 56: 79.
31. Hebart H.C., Bollinger P., Fisch J., Sarfati C., Meisner M., Baur J., et al. Analysis of T-cell responses to Aspergillus fumigatus antigens in healthy individuals and patients with hematological malignancies. Blood 2002, 100:4521-4528.
32. Nosanchuk J.D. Current status and future of antifungal therapy for systemic mycosis. Rec Patents Anti-Infect Drug Dis 2006, 1:75-84.